304 related articles for article (PubMed ID: 20083666)
1. Mechanisms of spatial and temporal development of autoimmune vitiligo in tyrosinase-specific TCR transgenic mice.
Gregg RK; Nichols L; Chen Y; Lu B; Engelhard VH
J Immunol; 2010 Feb; 184(4):1909-17. PubMed ID: 20083666
[TBL] [Abstract][Full Text] [Related]
2. GILT accelerates autoimmunity to the melanoma antigen tyrosinase-related protein 1.
Rausch MP; Irvine KR; Antony PA; Restifo NP; Cresswell P; Hastings KT
J Immunol; 2010 Sep; 185(5):2828-35. PubMed ID: 20668223
[TBL] [Abstract][Full Text] [Related]
3. Lymphatic endothelial cells induce tolerance via PD-L1 and lack of costimulation leading to high-level PD-1 expression on CD8 T cells.
Tewalt EF; Cohen JN; Rouhani SJ; Guidi CJ; Qiao H; Fahl SP; Conaway MR; Bender TP; Tung KS; Vella AT; Adler AJ; Chen L; Engelhard VH
Blood; 2012 Dec; 120(24):4772-82. PubMed ID: 22993390
[TBL] [Abstract][Full Text] [Related]
4. Transplantation of mouse HSCs genetically modified to express a CD4-restricted TCR results in long-term immunity that destroys tumors and initiates spontaneous autoimmunity.
Ha SP; Klemen ND; Kinnebrew GH; Brandmaier AG; Marsh J; Hangoc G; Palmer DC; Restifo NP; Cornetta K; Broxmeyer HE; Touloukian CE
J Clin Invest; 2010 Dec; 120(12):4273-88. PubMed ID: 21084750
[TBL] [Abstract][Full Text] [Related]
5. Autoimmune vitiligo does not require the ongoing priming of naive CD8 T cells for disease progression or associated protection against melanoma.
Byrne KT; Zhang P; Steinberg SM; Turk MJ
J Immunol; 2014 Feb; 192(4):1433-9. PubMed ID: 24403535
[TBL] [Abstract][Full Text] [Related]
6. Immune responses in a mouse model of vitiligo with spontaneous epidermal de- and repigmentation.
Eby JM; Kang HK; Klarquist J; Chatterjee S; Mosenson JA; Nishimura MI; Garrett-Mayer E; Longley BJ; Engelhard VH; Mehrotra S; Le Poole IC
Pigment Cell Melanoma Res; 2014 Nov; 27(6):1075-85. PubMed ID: 24935676
[TBL] [Abstract][Full Text] [Related]
7. Identification of Novel HLA-A*0201-Restricted CTL Epitopes in Chinese Vitiligo Patients.
Cui T; Yi X; Guo S; Zhou F; Liu L; Li C; Li K; Gao T
Sci Rep; 2016 Nov; 6():36360. PubMed ID: 27821860
[TBL] [Abstract][Full Text] [Related]
8. Engagement of NK receptor NKG2D, but not 2B4, results in self-reactive CD8+ T cells and autoimmune vitiligo.
Zloza A; Lyons GE; Chlewicki LK; Kohlhapp FJ; O'Sullivan JA; Lacek AT; Moore TV; Jagoda MC; Kumar V; Guevara-Patiño JA
Autoimmunity; 2011 Dec; 44(8):599-606. PubMed ID: 21913803
[TBL] [Abstract][Full Text] [Related]
9. Melanocyte-specific CD49a
Yokoi K; Watanabe R; Kume M; Yamane S; Tanaka A; Fujimoto M; Tanemura A
J Dermatol; 2023 May; 50(5):710-714. PubMed ID: 36514908
[TBL] [Abstract][Full Text] [Related]
10. Deletional self-tolerance to a melanocyte/melanoma antigen derived from tyrosinase is mediated by a radio-resistant cell in peripheral and mesenteric lymph nodes.
Nichols LA; Chen Y; Colella TA; Bennett CL; Clausen BE; Engelhard VH
J Immunol; 2007 Jul; 179(2):993-1003. PubMed ID: 17617591
[TBL] [Abstract][Full Text] [Related]
11. HLA-A2 restricted, melanocyte-specific CD8(+) T lymphocytes detected in vitiligo patients are related to disease activity and are predominantly directed against MelanA/MART1.
Lang KS; Caroli CC; Muhm A; Wernet D; Moris A; Schittek B; Knauss-Scherwitz E; Stevanovic S; Rammensee HG; Garbe C
J Invest Dermatol; 2001 Jun; 116(6):891-7. PubMed ID: 11407977
[TBL] [Abstract][Full Text] [Related]
12. Next-generation DNA re-sequencing identifies common variants of TYR and HLA-A that modulate the risk of generalized vitiligo via antigen presentation.
Jin Y; Ferrara T; Gowan K; Holcomb C; Rastrou M; Erlich HA; Fain PR; Spritz RA
J Invest Dermatol; 2012 Jun; 132(6):1730-3. PubMed ID: 22402439
[No Abstract] [Full Text] [Related]
13. Cytotoxic T lymphocyte reactivity to gp100, MelanA/MART-1, and tyrosinase, in HLA-A2-positive vitiligo patients.
Mandelcorn-Monson RL; Shear NH; Yau E; Sambhara S; Barber BH; Spaner D; DeBenedette MA
J Invest Dermatol; 2003 Sep; 121(3):550-6. PubMed ID: 12925214
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of experimental autoimmune vitiligo by oral administration of mushroom tyrosinase.
Zehtab T; Yazdanparast R; Rafieii S
Cytobios; 2001; 105(408):27-34. PubMed ID: 11368265
[TBL] [Abstract][Full Text] [Related]
15. Specific cytotoxic T lymphocyte responses against Melan-A/MART1, tyrosinase and gp100 in vitiligo by the use of major histocompatibility complex/peptide tetramers: the role of cellular immunity in the etiopathogenesis of vitiligo.
Palermo B; Campanelli R; Garbelli S; Mantovani S; Lantelme E; Brazzelli V; Ardigó M; Borroni G; Martinetti M; Badulli C; Necker A; Giachino C
J Invest Dermatol; 2001 Aug; 117(2):326-32. PubMed ID: 11511311
[TBL] [Abstract][Full Text] [Related]
16. A mouse model of vitiligo with focused epidermal depigmentation requires IFN-γ for autoreactive CD8⁺ T-cell accumulation in the skin.
Harris JE; Harris TH; Weninger W; Wherry EJ; Hunter CA; Turka LA
J Invest Dermatol; 2012 Jul; 132(7):1869-76. PubMed ID: 22297636
[TBL] [Abstract][Full Text] [Related]
17. A quantitative increase in regulatory T cells controls development of vitiligo.
Chatterjee S; Eby JM; Al-Khami AA; Soloshchenko M; Kang HK; Kaur N; Naga OS; Murali A; Nishimura MI; Caroline Le Poole I; Mehrotra S
J Invest Dermatol; 2014 May; 134(5):1285-1294. PubMed ID: 24366614
[TBL] [Abstract][Full Text] [Related]
18. CTLA-4 dysregulation of self/tumor-reactive CD8+ T-cell function is CD4+ T-cell dependent.
Gattinoni L; Ranganathan A; Surman DR; Palmer DC; Antony PA; Theoret MR; Heimann DM; Rosenberg SA; Restifo NP
Blood; 2006 Dec; 108(12):3818-23. PubMed ID: 16882704
[TBL] [Abstract][Full Text] [Related]
19. Molecular and functional bases of self-antigen recognition in long-term persistent melanocyte-specific CD8+ T cells in one vitiligo patient.
Mantovani S; Garbelli S; Palermo B; Campanelli R; Brazzelli V; Borroni G; Martinetti M; Benvenuto F; Merlini G; della Cuna GR; Rivoltini L; Giachino C
J Invest Dermatol; 2003 Aug; 121(2):308-14. PubMed ID: 12880423
[TBL] [Abstract][Full Text] [Related]
20. Why tyrosinase for treatment of melanoma.
Song YH
Lancet; 1997 Jul; 350(9071):82-3. PubMed ID: 9228956
[No Abstract] [Full Text] [Related]
[Next] [New Search]
